Langerhans Cell Histiocytosis
Conditions
Brief summary
Reactivation-free survival, Overall and disease free survival, To study the course of neurodegenerative CNS-LCH, Response of isolated tumorous CNS lesions to 2-CdA, Rate and spectrum of permanent consequences
Detailed description
Incidence of permanent consequences, Toxicity of treatment, Proportion fo patients alive and free of disease without permanent consequences, Cumulative incidence of reactivations in risk organs
Interventions
DRUGVinblastine Sulfate 1 mg/ml Solution for Injection or Infusion
DRUGOCTAGAM 10 %
DRUGLösung zur intravenösen Infusion
DRUGMercaptopurine Silver Pharma 50 mg tablets
DRUGINDOMETACIN CAPSULES BP 25mg
DRUGMethotrexate 10 mg Tablets
Sponsors
St. Anna Childrens Cancer Research Institute GmbH
Eligibility
Sex/Gender
All
Age
0 Years to 17 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reactivation-free survival, Overall and disease free survival, To study the course of neurodegenerative CNS-LCH, Response of isolated tumorous CNS lesions to 2-CdA, Rate and spectrum of permanent consequences | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of permanent consequences, Toxicity of treatment, Proportion fo patients alive and free of disease without permanent consequences, Cumulative incidence of reactivations in risk organs | — |
Countries
Austria, Belgium, Czechia, Denmark, Greece, Ireland, Italy, Netherlands, Norway, Poland, Spain, Sweden
Outcome results
None listed